Care Bears And Prenetics' IM8 Announce Global Partnership

Prenetics’ IM8 and Authentic Brands Group announced an exclusive 10-year worldwide partnership to launch Care Bears by IM8, with zero-sugar gummy multivitamins for children and adults targeted for global release in the first half of 2027. The products are planned for direct-to-consumer, subscription, e-commerce and retail channels; Prenetics CEO Danny Yeung said the ambition is to make the brand the world’s No. 1 gummy vitamin brand for kids and adults within the next few years.

Analysis

For PRE, the strategic value is more likely customer acquisition and channel expansion than near-term revenue: Care Bears could lower the trust and discovery barrier for family buyers, while retail distribution would test whether IM8 can extend beyond its existing premium, digitally led proposition. That is a meaningful option on a broader customer base, not yet evidence of a second growth engine. The press release provides no launch pricing, retailer commitments, royalty terms, unit economics, or forecast; the ambition to lead the category should not be treated as a financial target.

Authentic benefits from licensing and renewed use of its IP with relatively limited product execution exposure. PRE takes the operational burden: formulation and quality control, inventory, marketing, and the challenge of converting anniversary attention into repeat purchases. Established options such as Olly, SmartyPants, and major vitamin brands make shelf access alone insufficient; taste, trust, pricing, and subscription retention will determine economics. A family line could broaden IM8’s funnel, but a mass-market positioning or weak product experience could also blur its premium brand.

Timing matters: the announcement may support sentiment immediately, but commercial evidence is unlikely before the planned 2027 launch. Over 1–3 months, monitor disclosures on retailer commitments and launch investment. Over 6–18 months, the key tests are sell-through, repeat rates, customer-acquisition cost, and whether the new line adds customers rather than shifting existing IM8 demand. The thesis weakens if launch timing slips, distribution remains aspirational, or PRE signals material spending without measurable demand. Given the absence of economics and valuation context, this is a watch item, not a high-conviction trade.

Key Decisions for Investors

• Do not underwrite a material near-term earnings revision from the announcement alone; the launch is distant and unit economics are undisclosed.
• Keep PRE on a catalyst watchlist. Seek confirmation of named retail partners, launch pricing, royalty structure, and planned marketing or inventory investment before sizing a position.
• If PRE rallies on the partnership headline, avoid chasing without evidence of incremental demand. Reassess after launch using sell-through and repeat-purchase data, while checking for premium-line cannibalization.
• Falsify the positive option value if launch timing slips materially, retailer access does not become concrete, or management reports weak repeat rates or rising acquisition costs.